A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells

Clinical Cancer Research

Volumn 19, Issue 24, 2013, Pages 6787-6801

  Puig, Isabel ^a   Chicote, Irene ^a   Tenbaum, Stephan P ^a   Arqués, Oriol ^a   Herance, José Raúl ^a   Gispert, Juan D ^a   Jimenez, José ^a   Landolfi, Stefania ^b   Caci, Karina ^b   Allende, Helena ^b   Mendizabal, Leire ^a   Moreno, Debora ^b   Charco, Ramón ^b   Espín, Eloy ^b   Prat, Aleix ^a   Elez, Maria Elena ^b   Argilés, Guillem ^b   Vivancos, Ana ^a   Tabernero, Josep ^b   Rojas, Santiago ^a   Palmer, Héctor G ^a   more..

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

OXALIPLATIN; TRICIRIBINE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STEM CELL; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISTANT METASTASIS; DRUG RESPONSE; DRUG TARGETING; ENGRAFTMENT; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; MALE; METASTASIS POTENTIAL; MIDDLE AGED; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR XENOGRAFT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIVIDUALIZED MEDICINE; LIVER NEOPLASMS; MALE; MICE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890751776     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1740     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Globalcancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-8. (Pubitemid 30419092)
3. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
4. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-9.
5. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009;6:519-27.
6. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009;9:489-99.
7. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 2012;18:5314-28.
8. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts ("xeno-patients") identifies HER2 as an effective therapeutic target in cetux-imab-resistant colorectal cancer. Cancer Discov 2011;1:508-23.
9. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-5. (Pubitemid 46067311)
10. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10. (Pubitemid 46067310)
11. Pocard M, Tsukui H, Salmon RJ, Dutrillaux B, Poupon MF. Efficiency of orthotopic xenograft models for human colon cancers. In vivo (Athens, Greece) 1996;10:463-9. (Pubitemid 26359492)
12. Rashidi B, Gamagami R, Sasson A, Sun FX, Geller J, Moossa AR, et al. An orthotopic mouse model of remetastasis of human colon cancer liver metastasis. Clin Cancer Res 2000;6:2556-61. (Pubitemid 30399228)
13. Bikle DD, Munson S, Mancianti ML. Limited tissue distribution of the intestinal brush border myosin I protein. Gastroenterology 1991;100: 395-402.
14. Cespedes MV, Espina C, Garcia-Cabezas MA, Trias M, Boluda A, Gomez del Pulgar MT, et al. Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 2007;170:1077-85. (Pubitemid 47339374)
15. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780-3.
16. Aide N, Poulain L, Briand M, Dutoit S, Allouche S, Labiche A, et al. Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. Eur J Nucl Med Mol Imaging 2009;36:396-405.
17. Brepoels L, De Saint-Hubert M, Stroobants S, Verhoef G, Balzarini J, Mortelmans L, et al. Dose-response relationship in cyclophospha-mide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET. Eur J Nucl Med Mol Imaging 2010;37:1688-95.
18. Allen NE, Appleby PN, Roddam AW, Tjonneland A, Johnsen NF, Overvad K, et al. Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Clin Nutr 2008;88:1567-75.
19. Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3-deoxy-3-18F-fluorothymidine PET. J Nucl Med 2005;46:114-20. (Pubitemid 43086005)
20. Brepoels L, Stroobants S, Verhoef G, De Groot T, Mortelmans L, De Wolf-Peeters C. (18)F-FDG and (18)F-FLT uptake early after cyclo-phosphamide and mTOR inhibition in an experimental lymphoma model. J Nucl Med 2009;50:1102-9.
21. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008;26:317-25. (Pubitemid 351355126)
22. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S, et al. b-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012;18:892-901.
23. Kreso A, O'Brien CA. Colon cancer stem cells. Curr Protoc Stem Cell Biol 2008;Chapter 3:Unit 3 1.
24. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007;1:389-402. (Pubitemid 47506537)
25. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007;13: 3989-98. (Pubitemid 47037607)
26. Nemati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, Desjar-dins L, et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res 2010;16:2352-62.
27. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013;19:619-25.
28. De Sousa EMF, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013;19:614-8.
29. Network TCGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
30. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
31. Killion JJ, Fidler IJ. The biology of tumor metastasis. Semin Oncol 1989;16:106-15. (Pubitemid 19139648)
32. Sasaki O, Atkin WS, Jass JR. Mucinous carcinoma of the rectum. Histopathology 1987;11:259-72. (Pubitemid 17038274)
33. Yamamoto S, Mochizuki H, Hase K, Yamamoto T, Ohkusa Y, Yokoyama S, et al. Assessment of clinicopathologic features of colorectal mucinous adenocarcinoma. Am J Surg 1993;166: 257-61. (Pubitemid 24046429)
34. Bresalier RS, Niv Y, Byrd JC, Duh QY, Toribara NW, Rockwell RW, et al. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest 1991;87:1037-45.
35. Schwartz B, Bresalier RS, Kim YS. The role of mucin in colon-cancer metastasis. Int J Cancer 1992;52:60-5.
36. Niv Y. Mucin and colorectal cancer. Isr Med Assoc J 2000;2:775-7.
37. Monteiro J, Fodde R. Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer 2010;46: 1198-203.
38. Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 2004;64:4394-9. (Pubitemid 38856907)
39. Karst AM, Dai DL, Cheng JQ, Li G. Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apo-ptosis, and patient survival. Cancer Res 2006;66:9221-6. (Pubitemid 44521143)
40. Lewis JS, Achilefu S, Garbow JR, Laforest R, Welch MJ. Small animal imaging. current technology and perspectives for oncological imaging. Eur J Cancer 2002;38:2173-88. (Pubitemid 35223252)
41. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat Rev 2002;2:11-8. (Pubitemid 37328803)
42. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2001;2:157-64. (Pubitemid 33585927)
43. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics 2004;20:1453-4. (Pubitemid 38931415)